Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

BusinessWire_EN 
0 23.03.20
Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

BusinessWire_EN 
0 24.02.20
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein

BusinessWire_EN 
0 07.01.20
Stoke Therapeutics Added to NASDAQ Biotechnology Index


Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

BusinessWire_EN 
0 23.12.19
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

BusinessWire_EN 
0 26.11.19
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

BusinessWire_EN 
0 25.11.19
Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

BusinessWire_EN 
0 12.11.19
Stoke Therapeutics to Present at Upcoming Investor Conferences in November


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

BusinessWire_EN 
0 08.11.19
Health Canada bestätigt RavenQuest´s Technologie
​Das innovative kanadische Cannabisunternehmen RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB), informiert seine Aktionäre angesichts der jüngst erreichten signifikanten Meilensteine über
Lions_Investments 
0 10.08.19
RavenQuest BioMed – steigende Profitabilität bei sich beschleunigendem Wachstum
​Auf seiner aktuellen Roadshow berichtete der kanadische Kannabisproduzent RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB) ausführlich über die aktuelle Situation im Unternehmen. Demzufolge
Lions_Investments 
0 03.07.19
RavenQuest BioMed expandiert nach Europa
​Wie der stark wachsende kanadische Cannabishersteller RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB) mitteilte, hat man ein Abkommen über ein 50/50 Joint Venture mit der norwegischen Cannabis
Lions_Investments 
0 25.05.19
Cannabisproduktion steigt um 275 %
​Spitzen Nachrichten vom lizenzierten und staatlich anerkannten Cannabishersteller RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB). Wie das Unternehmen mitteilte, hat man die letzte Genehmigung
Lions_Investments 
0 09.04.19
RavenQuest bezieht hochwertige Cannabisstämme von alteingesessenem Profi
​In seiner jüngsten Unternehmensmeldung gab das kanadische Cannabisunternehmen RavenQuest BioMed (ISIN: CA7543871080 / CSE: RQB) bekannt, dass man ein Abkommen (‚Letter of Intent‘) unterzeichnet habe,
Lions_Investments 
0 17.02.19
Ravenquest BioMed, wohin geht es als nächstes?
Technische Analyse: Aus den letzten 200 Handelstagen errechnet sich für die Ravenquest BioMed-Aktie ein Durchschnitt von 0,46 USD für den Schlusskurs. Der Schlusskurs am letzten Handelstag lag....
Robert_Sasse 
0 02.08.19